A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin

Trial Profile

A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Solid tumours; Thrombocytopenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Dec 2017 Primary endpoint (Phase II: Effect of eltrombopag compared to placebo on the scheduled Day 1 pre-chemotherapy platelet counts will be evaluated across all cycles in the study) has not been met, according to the results published in the International Journal of Hematology
    • 01 Dec 2017 Results published in the International Journal of Hematology
    • 20 Apr 2016 Time frame for primary endpoints has been changed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top